In the present study, it was hypothesized that disruption of imprinting control in the H19/Igf2 domain may be a mechanism of ethanol-induced growth retardation-a key clinical feature of the fetal alcohol spectrum disorders (FASD). To test this prediction, genomic bisulphite sequencing was carried out on 473 bp of the H19 imprinting control region in DNA obtained from midgestation F(1) hybrid mouse embryos (C57BL/6 3 Mus musculus castaneus) exposed to ethanol during preimplantation development. Although ethanol-exposed placentae and embryos were severely growth retarded in comparison with saline-treated controls, DNA methylation at paternal and maternal alleles was unaffected in embryos. However, paternal alleles were significantly less methylated in ethanol-treated placentae in comparison with saline-treated controls. Partial correlations suggested that the relationship between ethanol and placental weight partly depended on DNA methylation at a CCCTC-binding factor site on the paternal allele in placentae, suggesting a novel mechanism of ethanol-induced growth retardation. In contrast, partial correlations suggested that embryo growth retardation was independent of placental growth retardation. Relaxation of allele-specific DNA methylation in control placentae in comparison with control embryos was also observed, consistent with a model of imprinting in which 1) regulation of allele-specific DNA methylation in the placenta depends on a stochastic interplay between silencer and enhancer chromatin assembly factors and 2) imprinting control mechanisms in the embryo are more robust to environmental perturbations.
INTRODUCTION
Ethanol is a classic teratogen capable of inducing a wide range of developmental abnormalities that vary in severity, from the barely perceptible to spontaneous abortion. These defects are collectively referred to as fetal alcohol spectrum disorders (FASD) [1] . Fetal alcohol syndrome lies at the extreme end of this spectrum and is associated with three broad domains: prenatal and/or postnatal growth retardation, distinctive facial features, and brain damage [2] . The etiological basis of FASD remains poorly understood. Prior research has focused on the role of growth factor levels [3, 4] , cellular proliferation [5, 6] , and genetic variation in enzymes that regulate alcohol metabolism (e.g., alcohol dehydrogenases) [7] . In recent years, attention has been directed to the possible role of epigenetics in the pathophysiology of chronic alcohol abuse in humans [8] . Comparatively little research has, however, been conducted into the role of epigenetic factors in FASD. This is surprising, considering that epigenetic mechanisms regulate a number of biological phenomena that could plausibly be involved in ethanol teratogenesis. Moreover, epidemiological and animal studies clearly indicate that the clinical variability of FASD is related to three distinct window periods: preconception, preimplantation, and gastrulation [5, [9] [10] [11] [12] [13] [14] [15] . These developmental windows are correlated with important periods of epigenetic reprogramming. Together with experimental evidence that ethanol inhibits DNA methyltransferase [16, 17] as well as one-carbon metabolism [18] , these correlations suggest a role for epigenetic mechanisms in the etiology of FASD.
With regard to possible epigenetic mechanisms, genomic imprinting is particularly interesting. Functionally haploid, imprinted genes are expressed primarily from either the paternal or maternal allele and are important regulators of fetal growth and development [19] . In addition, imprinted genes have been found to underlie a number of birth defect syndromes in humans [20, 21] and in animal species, including large offspring syndrome in ruminant species and cultureinduced growth abnormalities in mice [22] [23] [24] [25] [26] [27] [28] .
Imprinted genes are regulated by DNA methylation at differentially methylated regions (DMRs), of which there are two types: those that are differentially methylated in all tissues throughout development, and those that acquire differential methylation in a tissue-specific manner during somatic development [21] . The former are often referred to as ''imprinting control regions'' (ICRs) because they are the primary regulators of imprinting in their respective chromosomal domains [21] . Another general feature of imprinted genes is their tendency to appear in clusters [21] .
One of these clusters-an imprinted cluster on distal chromosome 7 in mouse (syntenic to chromosome 11p15.5 in humans)-contains at least two imprinted domains and eight imprinted genes [21] . One of these domains contains the bestcharacterized imprinted gene cluster in the mammalian genome: the Igf2/H19 domain, containing the paternally expressed Igf2 and maternally expressed H19 genes, as well as three DMRs associated with Igf2 and a single DMR associated with H19 [29] . The H19 DMR is considered an ICR because hypermethylation of the paternal allele is established during spermatogenesis and maintained during preimplantation and postimplantation development [30] [31] [32] [33] . Expression of Igf2 is regulated by the influence of the H19 ICR on higher-order chromatin structure in the region. The mechanism involves binding of CCCTC-binding factor (CTCF) to the H19 ICR, which prevents the physical interaction of Igf2 with enhancer elements located downstream of H19, partitioning the two genes into ''silent'' and ''active'' chromatin domains [34] . Maternal Igf2 is silenced because CTCF preferentially binds to the unmethylated maternal allele, whereas methylation on the paternal allele prevents binding, thus allowing Igf2 promoterenhancer interaction and expression of paternal Igf2 [34] . Perturbation of this process has deleterious effects on fetal growth because Igf2 is the precursor peptide for a mitogen factor known as ''insulin-like growth factor 2,'' which is active in fetal and placental tissues [19] . For example, hypomethylation of the H19 ICR has been associated with the SilverRussell birth defect syndrome, which is characterized by intrauterine growth retardation, poor postnatal health, classic facial features, and asymmetry [35] .
In the present study, it was hypothesized that ethanolinduced hypomethylation of the H19 ICR would be a mechanism of ethanol-induced growth retardation. In choosing the timing of exposure, it was decided to focus on the preimplantation period for the following reasons. First, the exposure of preimplantation embryos to high doses of ethanol in vivo is associated with normal implantation rates but severe growth retardation in late gestation [15] . Second, imprinting in the early embryo is sensitive to environmental conditions [36] . For example, the manipulation of the early embryo in culture has been associated previously with imprinting defects as well as high fetal resorption rates, gross physical abnormalities, and aberrant growth in the offspring surviving parturition [36] .
Because previous studies have shown that hypomethylation of the H19 ICR is associated with growth retardation in humans (e.g., Silver-Russell Syndrome [20] ), and that methylation occurs preferentially at the paternal allele [30] [31] [32] [33] , it was predicted that ethanol exposure during the preimplantation period would be associated with 1) embryo and placental growth retardation and 2) hypomethylation at the paternal allele of the H19 ICR, and that 3) the effect of ethanol on embryonic and placental growth would be dependent on methylation at the paternal allele of the H19 ICR.
MATERIALS AND METHODS

Materials
To distinguish parental genetic contributions, it was necessary to use two different mouse strains. The C57BL/6JOlaHsd (C57BL/6) strain, purchased from the National Health Laboratory Service (Johannesburg, South Africa), served as the maternal genetic source, whereas the Mus musculus castaneus (CAST/Ei) strain, purchased from the Jackson Laboratory (Bar Harbor, ME), served as the paternal genetic source.
Ten female C57BL/6 mice were randomly assigned to two groups: ethanoltreated and control. It was originally planned that these females would be mated with a single male (''CAST male 1'') to keep sources of variation to a minimum. However, only a single pregnancy was derived from CAST male 1 before he became sterile, necessitating a replacement male. Thus, ''CAST male 2,'' the male offspring of CAST male 1, was used to generate the nine remaining pregnancies.
The study received ethics approval from the Animal Ethics Control Committee of the University of the Witwatersrand. Animals were handled in accordance with the animal care procedures of the Animal Ethics Control Committee of the University of the Witwatersrand.
Methods
All experimental steps were done at separate locations. In addition, all molecular biology experimental steps were done using dedicated sets of pipettes. Great care was taken to keep working areas, equipment, and pipettes free of DNA contamination, including regular use of sodium hypochlorite and ultraviolet irradiation. The bisulphite modifications, DNA extractions, and DNA digestions were done in a separate laboratory, in a separate building, from the cloning and PCR steps. The preparation of PCR reaction mixes was done in a separate room from post-PCR steps.
The generation of mouse pregnancies involved the following procedure. A single C57BL/6 female was placed with a CAST/Ei male in the evening. The presence of a vaginal plug the following morning was taken as evidence of copulation and that day was scored as 0.5 days after coitus (0.5 dpc). The experimental treatments followed an acute dosage regimen paradigm: at 1.5 and 2.5 dpc, 0.015 ml/g of 25% ethanol (2.9 g/kg) was administered to putatively pregnant females. This dosage was modeled on Padmanabhan and Hameed [15] , who reported severe growth retardation in midgestation mouse embryos after administration of 5.8 g/kg ethanol on one of the first 6 days after coitus (1.5-6.5 dpc) in mouse. A volumetric equivalent of PBS was administered to control females. Food and water were withheld from control females for a minimum of 2 h after gavage to partially mimic the anorectic effect of ethanol.
At 10.5 dpc, pregnant females were euthanized, and their placentae and embryos were harvested. The amniotic and chorionic sacs were completely dissected from the embryonic and placental tissues and discarded. Great care was taken to exclude maternally derived tissue from the placenta.
Placentae and embryos were subsequently weighed on a regularly calibrated Sartorius scale with 0.001-g readability.
DNA Extractions
DNA was extracted from the embryos and placentae using the High Pure PCR Template Preparation Kit (Roche Applied Science) according to the manufacturer's instructions, with the exception that ethylenediaminetetraacetic acid was added to the elution buffer to a final concentration of 10 mM. DNA concentrations were determined on a Nanodrop ND-1000 spectrophotometer. Embryonic and placental DNA samples were subsequently pooled so that there were 20 samples in total: 10 embryonic and 10 placental DNA samples from 10 mothers.
Restriction Enzyme Digests
The pooled DNA samples were digested using the HindIII restriction endonuclease (New England Biolabs), which cuts outside of the region of interest. Briefly, 5 lg of DNA was digested using 10 units of restriction enzyme at 378C overnight (12-16 h) according to the manufacturer's instructions. Digested DNA was purified using a phenol:chloroform:isoamyl alcohol (25:24:1) protocol. To increase the amount of precipitated DNA, glycogen was added to the aqueous phase to a final concentration of 0.5-1 lg/ll. DNA was precipitated using a salting-out procedure and stored in Tris buffer (pH 8.0).
Bisulphite Modification
Digested DNA samples were subjected to bisulphite mutagenesis using the CpGenome modification kit from Chemicon (Temecula, CA). The procedure was done according to the manufacturer's instructions, with the exception that the first denaturation step was done in 10 mM NaOH and incubated at 968C for 5 min. After addition of the first modification reagent, samples were incubated at 558C overnight (12-14 h) in the dark.
Amplification of the H19 ICR by PCR
Bisulphite-modified DNA was subsequently amplified by two rounds of PCR using a nested set of primers specific for nucleotides 1278 to 1706 in the U19619 genomic contig [37, 38] . The region amplified corresponds to the upstream portion of the H19 ICR and includes 16 and 17 CpG dinucleotides in the C57BL/6 and CAST/Ei strains, respectively [31] . The entire H19 ICR includes four GC-rich DNA-binding sites for CTCF, a zinc finger protein that preferentially binds unmethylated DNA and which is required for the insulator function of the H19 ICR [39] [40] [41] [42] [43] [44] [45] [46] . The region amplified by the PCR primer set of the present study includes two of these CTCF DNA-binding sites: CTCF1 and CTCF2, located at positions 1359-1402 and 1603-1648 in the U19619 genomic contig respectively [31] . Methylation occurs at six CpG dinucleotides in CTCF1 and five CpG dinucleotides in CTCF2. This is shown schematically in Figure 1 .
The first round of PCR included the following primers, with their position in the U19619 genomic contig indicated in parentheses: H19for1 (1278-1302), ETHANOL-INDUCED GROWTH RETARDATION AND THE H19 ICR Bioline); MgCl 2 (2 mM; Applied Biosystems); and 1 unit of AmpliTaq Gold DNA polymerase (0.02 U/ll; Applied Biosystems). First-round PCR was carried out in a GeneAmp 2720 thermal cycler (Applied Biosystems) for two cycles at 948C (4 min), 558C (2 min), and 728C (2 min), followed by 35 cycles at 948C (1 min), 558C (2 min), and 728C (2 min). One microliter of the firstround PCR reaction was used as template in the second round, using the following set of nested primers, with their position in the U19619 genomic contig indicated in parentheses: H19for2 (1304-1328), 5
0 -GTAAGGAGATT ATGTTTATTTTTGG-3 0 and H19rev2 (1705-1726), 5 0 -CCTCATAAAACC CATAACTAT-3 0 . The above primers correspond to the BS2t1/BS1t3, BS2t2/ BS1t4 primer sets reported in Tremblay et al. [30] , with the exception of position 1711-1714 in BS1t4, which was mistakenly reported as TAAT instead of AAAA. The PCR mix was identical to the first round, with the exception that the final volume was made up to 25ll in deionized water. The thermocycler conditions were also identical, with the exception that the first two cycles were omitted.
Cloning of PCR Products
The resulting PCR products were cloned using a pGEM T-easy vector system according to the manufacturer's instructions (Promega) and were transformed into competent DH5a cells prepared according to the rubidium chloride method. Colonies containing the insert of interest were identified by blue/white colony screening. Clones were subsequently amplified by PCR using the same primers and procedures described for second-round nested PCR.
The PCR products were filter purified using MultiScreen PCR l96 plates, in accordance with the manufacturer's instructions (Millipore). Purified products were resuspended in 20 ll of deionized water, 5-6.5 ll of which was used as template for dideoxy chain-termination-based sequencing. In brief, a one-eighth reaction of BigDye Terminator v3.1 reaction mix (Applied Biosystems), together with reverse primer (H19rev2) was made up to 10 ll in deionized water and incubated in a GeneAmp 2720 thermal cycler for 25 cycles at 968C (30 sec), 508C (15 sec), and 608C (4 min). The resulting cycle sequencing products were filter purified on Montage SEQ 96 cleanup plates, in accordance with the manufacturer's instructions (Millipore).
Purified cycle sequencing products were resolved by capillary electrophoresis on a 3130xl Genetic Analyzer (Applied Biosystems). Sequence data were generated by Ultra-Rapid sequencing using the 36-cm capillary array and the 3130 POP-7 polymer (Applied Biosystems). The raw sequence data were analyzed using Sequencing Analysis v5.2 to generate sequence files in .abi format (Applied Biosystems).
During the next stage, the relevant sequence information was extracted. This included whether the sequence contained C57BL/6 or CAST/Ei alleles, the amount of non-CpG Cs, and the status of each CpG site (i.e., whether it was a TpG or a CpG). CpG and TpG sites correspond to methylated and unmethylated cytosines, respectively.
Statistical Analyses
The data of the present study are hierarchically structured (i.e., measurements of level 1 units are nested within level 2 units). For example, weight measurements are taken at the level of embryos and their placentae, which are nested within mothers. Similarly, methylation measurements are taken at the level of clones, which are also nested within mothers. As a consequence of this hierarchical data structure, not all observations are independent (i.e., measurements that come from the same mother are related). Taking this data structure into account, it was decided to employ hierarchical linear modeling (HLM) [47] in the testing of the a priori predictions of the present study. All analyses were done in MLwiN v2.02, downloaded from the Centre for Multilevel Modelling Web site [37, 48] .
Hierarchical linear modeling is an extension of simple linear regression, in which the relationship between two variables is expressed as:
where y is the dependent variable; a is the intercept; b is the coefficient or slope of x, the predictor variable; e is the residual variation not explained by the model; and i takes on values of 1 to the number of observations. What makes a model hierarchical is the nature of the residual variation. In a variance component model (a restricted form of the hierarchical linear model), the regression equation is rewritten as:
where a and b are the fixed parts of the model; u j represents the deviation of the jth level 2 unit from the predicted value; and e ij represents the deviation of the ith level 1 unit, nested within the jth level 2 unit, from the predicted value.
The above hierarchical linear model (equation 2) was adapted to the present study to test the relationship between treatment (ethanol vs. control) and weight, as well as between treatment and DNA methylation. Thus, in equation 2, y corresponds to either weight or DNA methylation, and x corresponds to treatment, a dummy variable with ethanol coded 1 and control coded 0. Moreover, u j represents the deviation of the jth mother from the predicted value, and e ij represents the deviation of the level 1 unit, nested within the jth mother, from the predicted value. With regard to the weight data, e ij corresponds to the deviation of the ith embryo or placenta from the predicted value. For the DNA methylation data, e ij corresponds to the deviation of the ith clone from the predicted value.
The same general strategy was employed to test the hypotheses that treatment predicts 1) embryo weight, 2) placental weight, and 3) DNA methylation. First, log likelihood ratio tests compared the full model (equation 2) with the reduced model:
where only the intercept (a) is taken as a predictor of the dependent variable. A significant test statistic indicates that the full model (equation 2) is a significantly better predictor of the dependent variable than the reduced model (equation 3). In the second step, the significance of the coefficient (b) of the treatment predictor term is assessed by t-tests. These were one sided with regard to the effect of treatment on weight because of the a priori prediction that ethanol would induce growth retardation. Similarly, the t-tests of the relationship between ethanol and DNA methylation were also one sided, given the a priori prediction that ethanol would induce hypomethylation. However, it should be noted that, given the skew in methylation data, which tends to be either high or low, the assumptions of the t-test may be violated. Because the log likelihood ratio test is less sensitive to deviations from normality, it is a more reliable indicator of the relationship between treatment and DNA methylation.
The subsequent analyses were all conducted in SPSS for Windows v13.0 (SPSS Inc., Chicago IL).
To assess the three-way relationship between treatment, weight, and DNA methylation, it was necessary to aggregate both datasets to the level of mothers. The reason for this was that DNA methylation was assessed in pooled DNA samples and not for individual embryos and their placentae. The relationship between treatment and the aggregated data was tested by Mann-Whitney U tests. 
HAYCOCK AND RAMSAY
The two-way relationships between weight, DNA methylation, and treatment were subsequently assessed by calculating Spearman correlation coefficients, except in cases of tied ranks, in which case Kendall tau-b was used instead. The two-way correlations were followed up by partial correlations of the relationship between weight and treatment, controlling for the effect of DNA methylation on weight. By comparing the resulting reduction in the correlation coefficient between treatment and weight, it is possible to assess whether this relationship is wholly or in part dependent on DNA methylation. For example, if the correlation coefficient is reduced to zero, this would indicate that the relationship between ethanol and weight is entirely dependent on DNA methylation. This would be consistent with the hypothesis that ethanol indirectly affects weight (i.e., affects weight via its effect on DNA methylation). Alternatively, if the correlation coefficient remained the same, this would indicate that the relationship is entirely independent of DNA methylation. However, this would not prove that DNA methylation causally mediates the relationship between treatment and weight. To determine whether the reduction in the correlation between treatment and weight after adjusting for DNA methylation (i.e., the indirect effect) was significant, 95% confidence intervals were calculated using a nonparametric bootstrapping procedure described by Preacher and Hayes [49] .
Statistical significance was set at 0.05.
RESULTS
Weight Data
The mean embryonic weights for the control and ethanol treatment groups were 48.4 mg (SD, 17.2 mg) and 19.8 mg (SD, 6.5 mg), respectively. The mean placental weights for the control and ethanol treatment groups were 50.5 mg (SD, 16.5 mg) and 33.4 mg (SD, 12.2 mg), respectively. These differences were highly significant, as indicated by log likelihood ratio tests of treatment type (ethanol vs. control) in hierarchical linear models of embryo (P , 0.001) and placenta (P , 0.01) weight. After aggregation of the data to the level of mothers, the median embryo weights in the control and ethanol groups were 51.81 mg and 18.06 mg (P , 0.01), respectively, whereas the median placenta weights in the control and ethanol groups were 49.38 mg and 34.51 mg (P , 0.01), respectively.
In contrast to the significant weight differences, the number of successful implantations (P . 0.60) and resorption rates (P . 0.10) were not significantly different between the two treatment groups.
Confirmation of Strain-Specific DNA Polymorphisms
Sequencing of adult C57BL/6 and CAST/Ei mice, as well as pooled DNA samples from embryos and placentae, confirmed the presence of T-C and G-A transitions at the nucleotide positions 1506 and 1566, respectively, in the U19619 genomic contig. Two additional mutations were identified in the same samples; namely, a G INDEL (deletion absent in the C57BL/6 strain) and an A-G transition (A in C57BL/6) at nucleotide positions 1501-1506 and 1654, respectively, in the U19619 genomic contig.
Analyses of DNA Methylation
Of 594 clones sequenced, 257 were discarded, leaving 337 clones in total for the analyses. Criteria for excluding a clone included the following: a nonconversion error rate of unmethylated cytosine to thymine .5%, which indicated inefficient bisulphite mutagenesis; and whether any ambiguities existed in the parental origin of a clone (i.e., the presence of a paternal and maternal sequence variant on the same clone). The latter accounted for about 25% of the discarded clones and may have resulted from ''template switching''-a PCR artifact-during nested PCR of bisulphite-modified DNA.
The number of clones representing each treatment group was evenly split, with 144 and 148 coming from ethanolexposed and control samples, respectively. In total, 165 and 127 clones were inherited paternally and maternally, respectively, indicating a slight bias in favor of paternal clones. Figure 2 describes the DNA methylation profiles for 10 embryos and 10 placentae derived from five control and five ethanol-treated mothers, constructed from 292 clone sequences. Figure 3 describes the aggregated data (i.e., with DNA methylation levels averaged over clones).
Maternal and paternal alleles were clearly hypomethylated and hypermethylated, respectively, in embryos and placentae (Figs. 2 and 3) . However, the relationship between parental origin and DNA methylation is less striking in placentae, with generally less methylation on the paternal allele and more methylation on the maternal allele in comparison with embryos. Focusing on the nonaggregated data, several maternal clones are characterized by blocks of methylation, whereas several paternal clones are characterized by blocks of demethylation (Fig. 2) .
With respect to the effect of exposure, ethanol-treated and control embryos were broadly similar in their DNA methylation profiles at both paternal and maternal alleles (Figs. 2 and  3 ). In contrast, the pattern of methylation at paternal and maternal alleles in placentae appears to correspond with exposure status, with ethanol-treated paternal alleles carrying less methylation, particularly around CpG sites 1 through 6, and ethanol-treated maternal alleles carrying more methylation, particularly around CpG sites 12 through 16, in comparison with control placentae.
HLM of DNA Methylation
Hierarchical linear modeling was used to test the relationship between DNA methylation and treatment (Table 1) . Log likelihood ratio tests indicated that the treatment predictor term (with control coded 0) significantly improved the model of total paternal allele DNA methylation in placentae (P , 0.05; Table 1 ). Analysis of the model parameters indicated that paternal clones from ethanol-exposed placentae were significantly less methylated (12% on average; P , 0.05) than paternal clones from control placentae ( Table 1) . Log likelihood ratio tests also indicated that the above difference in methylation originated primarily from the CTCF1 (P , 0.01) and not the CTCF2 (P . 0.10) region. The former carried, on average, 22% less methylation than paternal CTCF1 alleles from control placentae (P , 0.01; Table 1 ).
The treatment predictor term was not found to significantly improve any other models of DNA methylation, although trends for an improvement were observed for total DNA methylation, as well as DNA methylation at the CTCF2 site, on the maternal allele in placentae (P , 0.10; Table 1 ).
Analyses of the Aggregated DNA Methylation Data
After aggregating the data to the level of mothers (i.e., by averaging over clones), paternal allele DNA methylation in placentae remained significantly different between ethanoltreated and control mothers in terms of both total and CTCF1 DNA methylation (P , 0.05; Table 2 ). Mann-Whitney U tests revealed no other significant differences in DNA methylation (in each case, P . 0.10; Table 2 ).
The Relationship Between Treatment and Weight Adjusted for Paternal Allele DNA Methylation
The raw correlations between weight and treatment, with controls as the reference category, were À0.866 (P , 0.01) and À0.801 (P , 0.01) for placental and embryonic samples, 
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HAYCOCK AND RAMSAY respectively, indicating very large and significant reductions in weight in the ethanol-exposed group. Partial correlations were carried out to determine whether this relationship was statistically dependent on paternal allele DNA methylation in placentae, as well as whether the relationship between treatment and embryo weight was statistically dependent on placental weight. Spearman rank correlations revealed highly significant relationships between placental weight and total paternal allele DNA methylation (r ¼ 0.767; P , 0.01), as well as CTCF1 paternal allele DNA methylation (r ¼ 0.767; P , 0.01), in placentae. With regard to paternal allele DNA methylation at CTCF2 in placentae, no significant correlations with embryo or placental weight were observed (in each case, P . 0.10). Embryo weight was not significantly correlated with total or CTCF1 paternal allele DNA methylation in placentae (in each case, P . 0.10). 
ETHANOL-INDUCED GROWTH RETARDATION AND THE H19 ICR
Ethanol-treated placentae were, on average, 15 mg smaller than control placentae. Partial correlations indicated that the relationship between placental weight and treatment decreased by 40% after adjustment for paternal allele DNA methylation at CTCF1. Although causality cannot be proven by this analytical approach, this is consistent with a scenario in which DNA methylation at the paternal CTCF1 allele mediates ;40% of the relationship between treatment and placental weight; that is, 6 mg of the 15-mg difference in weight (95% confidence interval [CI], À11.2 mg, 0 mg). Similarly, the relationship between placental weight and total paternal allele DNA methylation decreased by ;25%. This is consistent with, but does not prove, a scenario in which 3.7 mg of the 15-mg difference in weight is mediated by total paternal allele DNA methylation (95% CI, À15.9 mg, 1.2 mg). Although these results are of borderline statistical significance, they suggest that the relationship between treatment and placental weight was more strongly dependent on paternal allele DNA methylation at CTCF1 in comparison with total paternal allele DNA methylation. Partial correlations also indicated that the correlation between ethanol and embryo weight was statistically independent of placental weight (À4.3 mg; 95% CI, À20.8 mg, 7.8 mg).
DISCUSSION
Growth Retardation in the Ethanol Treatment Group
The finding of ethanol-induced growth retardation is in close agreement with previous studies employing in vivo administration of ethanol during the preimplantation period [14, 15, 50] . This is in stark contrast to the findings of studies that employed in vitro routes of administration, which generally reported enhanced preimplantation but unaffected postimplantation embryo development [51] .
The relationship between ethanol exposure during the preimplantation period and placental growth has received comparatively little attention. In a study by Padmanabhan and Hameed [15] , the effect on placental weight was found to be highly variable. Administration of 0.02 ml/g or 0.03 ml/g of 25% ethanol at either 1.5 or 2.5 dpc resulted in growth enhancement of placentae at 15.5 dpc, relative to saline-treated but not untreated controls. However, placentae harvested at either 14.5 or 18.5 dpc were unaffected after administration of 0.03 ml/g of 25% ethanol at 2.5 dpc. When the day of administration was shifted to 6.5 dpc, the placental weights were reduced in comparison with controls at both 14.5 and 18.5 dpc [15] . Their results suggest that the effect of ethanol, administered during the preimplantation and peri-implantation periods, depends on dosage as well as timing. Future studies should more firmly establish the relationship between ethanol administration during the preimplantation period and placental growth.
Relaxation of Allele-Specific DNA Methylation
Greater levels of methylation on the maternal allele and lower levels of methylation on the paternal allele were observed in control placentae in comparison with control embryos, suggesting that the control of allele-specific DNA methylation was relatively more relaxed in placentae. This parallels the findings of Mann et al. [52] , who reported sporadic losses of methylation on the normally hypermethylated paternal and maternal alleles of the H19 and Snrpn ICRs, respectively, in 9.5 dpc control placentae, relative to control embryos.
In addition, Svensson et al. [53] reported sporadic activation of the normally silent paternal H19 gene in tissue of trophectoderm origin, but not the inner cell mass and the postimplantation embryo. Svensson et al. [53] also reported activation of paternal H19 in placenta but not the embryo after exposure to trichostatin-A, an inhibitor of histone deacetylase.
Although it was not determined in the current study whether relaxation of allele-specific DNA methylation corresponded to relaxation of imprinted gene expression, these findings are consistent with a model of more stringent imprinting control in the embryo in comparison with tissues of trophectoderm origin. From an evolutionary perspective, the consequences of relaxed imprinting are more serious for the embryo, which must maintain imprinted expression for a considerably longer period of time in comparison with the placenta. Thus, it is reasonable to propose selective pressure for more stringently regulated imprinting in the embryo.
The above data are also consistent with a model of genomic imprinting in which allele-specific DNA methylation depends on a stochastic interplay between chromatin assembly factors and ICRs. For example, CTCF, a DNA-binding protein with an affinity for unmethylated DNA, is required for maintaining the H19 ICR in an unmethylated state [54] . Because CTCF is present in finite amounts, sporadic fluctuations below a certain threshold may lead to sporadic gains in methylation on the maternal allele. This effect would be exacerbated by the presence of extra ''maternal copies'' of H19 (e.g., as a result of ethanol-induced [present study] or culture-induced [52] demethylation of the paternal allele), which might place demands on CTCF beyond the available supply. As a consequence, some maternal copies of H19 might go unprotected, leading to sporadic gains of DNA methylation and, possibly, silencing of maternal H19. The less stringently maintained state of allele-specific DNA methylation in the placenta in comparison with embryos may underlie its greater sensitivity to the environment. The relatively lower levels of paternal allele DNA methylation in ethanoltreated placentae observed in the present study could have arisen directly (e.g., through ethanol-induced inhibition of DNA methyltransferase [17] ) or indirectly (e.g., as a result of an anorectic effect on diet). Given the known relationship between diet and DNA methylation [55] , it is possible that the observed DNA methylation changes were the result of reduced food intake in the ethanol-fed dam and not ethanol per se. Although food and water were withheld from control dams for a minimum of 2 h after gavage, this may not be an adequate control.
Regardless of whether the association is directly due to alcohol or reduced food intake, the fact that embryos were exposed prior to gastrulation suggests that: 1) DNA methylation at the paternal allele was reduced in both the inner cell mass and the trophectoderm but recovered in the descendents of the former (the postimplantation embryo) but not the latter (the placenta) and 2) demethylation occurred preferentially in the outer layer of the early-stage blastocyst/morula, as a result of its closer proximity to the maternal environment.
Two possible mechanisms of the first hypothesis (i.e., preferential recovery of allele-specific DNA methylation in the postimplantation embryo) include: 1) preferential selection in the inner cell mass of unaffected cells and/or 2) the presence of recovery mechanisms in the gastrulating embryo but not the trophectoderm. Although a selection-based mechanism cannot be entirely ruled out, H19 is not expressed in the embryo until 8.5. dpc [56] , suggesting that paternal H19 methylation is not functional in the inner cell mass. The second proposed mechanism of recovery is consistent with the wave of genomewide de novo DNA methylation associated with the onset of gastrulation in the inner cell mass around embryonic days 4.5 to 7.0 [57, 58] . The de novo DNA methyltransferases Dnmt3a and Dnmt3b, which have an established role in the maintenance and acquisition of methylation at imprinted loci [59] [60] [61] , are particularly interesting in this regard because they preferentially locate to the inner cell mass during gastrulation [62] . Thus, the putative recovery of the demethylated paternal allele in the inner cell mass and postimplantation embryo may be mediated by de novo methylation, catalyzed by Dnmt3a and Dnmt3b, whereas the absence of these enzymes in trophectoderm may explain the persistence of demethylation in 10.5 dpc placentae.
The results of the present study are in close agreement with Mann et al. [52] , who reported loss of imprinted expression of H19, Ascl2, Snrpn, Peg3, and Xist in mouse conceptuses after in vitro culture in Whitten medium. These changes were associated with reduced methylation at the normally hypermethylated alleles of the H19 and Snrpn ICRs in preimplantation mouse blastocysts, which persisted into postimplantation mouse placentae but not embryos harvested at 9.5 dpc.
Ethanol-Induced Demethylation as a Mechanism of Growth Retardation
Despite being unrelated to embryo weight, analysis of partial correlations suggested that 40% of the relationship between ethanol and placental weight depended on paternal allele DNA methylation at CTCF1. This statistical relationship reflects a reduction in the correlation coefficient between alcohol and placental weight adjusting for paternal allele DNA methylation at CTCF1 in placentae, and it does not prove that DNA methylation causally mediated the relationship. It is possible that ethanol affected growth and DNA methylation via independent pathways. Moreover, in the absence of expression data, it is impossible to know whether imprinted gene expression was disrupted in the H19/Igf2 domain, further limiting the ability of the present study to infer functional effects of reduced paternal allele DNA methylation.
Although causality cannot be proven, the data are consistent with a functional effect of alcohol-induced paternal allele demethylation in placentae, perhaps as a result of disrupted imprinting control in the H19/Igf2 domain. Because abrogation of CTCF-binding sites on the paternal allele results in the epigenetic switching of the paternal to the maternal epigenotype [63] , it is hypothesized that ethanol-induced demethylation at the paternal H19 ICR might result in a similar switching in placentae. This epigenetic switch could result in placental growth retardation as a result of reduced Igf2 protein levels, which could occur via two mechanisms: 1) binding of CTCF to the hypomethylated paternal allele of the H19 ICR, and thus partitioning of the paternal Igf2 gene into a silent chromatin state, and/or 2) negative interactions between paternal allele H19 RNA and Igf2 [64] [65] [66] [67] [68] . Alternatively, a role for H19 in growth control independently of Igf2 cannot be ruled out [69] .
